Pacific Biosciences of California, Inc.
PACB · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $160M | $154M | +3.9% |
| Operating income | −$554M | −$474M | −16.8% |
| Net income | −$546M | −$310M | −76.3% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $40.6M | $38.4M | +5.7% |
| Operating income | −$37.0M | −$38.9M | +4.9% |
| Net income | −$37.8M | −$38.0M | +0.5% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Pacific Biosciences of California's revenue in FY2025?
- $160M in FY2025 (Fiscal year ended Dec 31, 2025), +3.9% vs $154M a year earlier, per its 10-K filed Feb 2026.
- Was Pacific Biosciences of California profitable in FY2025?
- No: net income was −$546M and operating income −$554M in FY2025.
- What was Pacific Biosciences of California's revenue in Q3 2026?
- $40.6M (+5.7% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.